What question did this study set out to answer?

This trial investigates the effectiveness of acalabrutinib in managing tumor burden before and after allo-HCT in patients with relapsed mantle cell lymphoma.

July 19, 2026Annals of HematologyOpen Access

Acalabrutinib in patients with mantle cell lymphoma subjected to allogeneic hematopoietic cell transplantation. a phase 2 study by the Polish Lymphoma Research Group (PLRG12 trial)

View Full Paper

Ask AI

Bookmark

Authors

SGSebastian GiebelSilesian University of Technology ACAnna CzyżWroclaw Medical University IHIwona HusMinistry of Interior

Discussion

Member takes

Implication

Phase 2 trial evaluates acalabrutinib's efficacy and safety in relapsed MCL before and after transplantation.

Key Points

This trial investigates the effectiveness of acalabrutinib in managing tumor burden before and after allo-HCT in patients with relapsed mantle cell lymphoma.
Phase 2 trial involving 28 patients treated with acalabrutinib 100 mg BID for 3-6 months.
Patients achieving CR or PR were referred for allo-HCT, followed by acalabrutinib maintenance.
Adverse events were monitored, with specific attention to severe complications.
Overall response rate was 57% with 50% achieving CR and 7% PR.
Two-year overall survival was 60% (95% CI, 40-79); progression-free survival was 41.5% (23-60).
79% of patients experienced grade 3-4 adverse events, with infections being the most common.

Cite This Study

Giebel et al. (2026) studied this question.

synapsesocial.com/papers/6a5c6970118b92953e3edcbb https://doi.org/10.1007/s00277-026-07178-8

View Full Paper

Ask AI

Bookmark

July 19, 2026Annals of HematologyOpen Access

Acalabrutinib in patients with mantle cell lymphoma subjected to allogeneic hematopoietic cell transplantation. a phase 2 study by the Polish Lymphoma Research Group (PLRG12 trial)

View Full Paper

Ask AI

Bookmark

Authors

SGSebastian GiebelSilesian University of Technology ACAnna CzyżWroclaw Medical University IHIwona HusMinistry of Interior

Discussion

Member takes

Implication

Phase 2 trial evaluates acalabrutinib's efficacy and safety in relapsed MCL before and after transplantation.

Key Points

This trial investigates the effectiveness of acalabrutinib in managing tumor burden before and after allo-HCT in patients with relapsed mantle cell lymphoma.
Phase 2 trial involving 28 patients treated with acalabrutinib 100 mg BID for 3-6 months.
Patients achieving CR or PR were referred for allo-HCT, followed by acalabrutinib maintenance.
Adverse events were monitored, with specific attention to severe complications.
Overall response rate was 57% with 50% achieving CR and 7% PR.
Two-year overall survival was 60% (95% CI, 40-79); progression-free survival was 41.5% (23-60).
79% of patients experienced grade 3-4 adverse events, with infections being the most common.

Cite This Study

Giebel et al. (2026) studied this question.

synapsesocial.com/papers/6a5c6970118b92953e3edcbb https://doi.org/10.1007/s00277-026-07178-8

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark